US 12,421,507 B2
Methods and compositions for optochemical control of CRISPR-CAS9
Amit Choudhary, Boston, MA (US); Debasish Manna, Boston, MA (US); Basudeb Maji, Cambridge, MA (US); and Soumyashree Ashok Gangopadhyay, Boston, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); and The Brigham and Womens's Hospital, Inc., Boston, MA (US)
Appl. No. 17/270,196
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US); and THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US)
PCT Filed Aug. 20, 2019, PCT No. PCT/US2019/047357
§ 371(c)(1), (2) Date Feb. 22, 2021,
PCT Pub. No. WO2020/041380, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/773,997, filed on Nov. 30, 2018.
Claims priority of provisional application 62/765,346, filed on Aug. 20, 2018.
Prior Publication US 2021/0317429 A1, Oct. 14, 2021
Int. Cl. C12N 9/22 (2006.01); C07D 239/49 (2006.01); C07D 405/14 (2006.01); C12N 15/90 (2006.01)
CPC C12N 9/22 (2013.01) [C07D 239/49 (2013.01); C07D 405/14 (2013.01); C12N 15/907 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A CRISPR system comprising:
a. a CRISPR enzyme comprising one or more destabilizing domains; and
b. one or more photocaged ligands comprising at least one photocage molecule having a chemical structure comprising:

OG Complex Work Unit Chemistry
wherein, upon exposure to UV or visible light, the one or more photocaged ligands can bind to the one or more destabilizing domains.